Insperity price target lowered to $71 from $74 at Roth Capital

Roth Capital analyst Jeff Martin lowered the firm’s price target on Insperity (NSP) to $71 from $74 and keeps a Buy rating on the shares. Elevated healthcare claims have decimated the company’s profitability this year, though the firm remains positive on the anticipated benefit from repricing new and renewing clients, the updated agreement with United that spreads risk sharing, and the potential long-term benefit of the partnership with Workday (WDAY), the analyst tells investors in a research note.